SCHIZOPHRENIA
Recruiting for Phase 2 Study
We are currently recruiting for our Phase 2 study to evaluate the efficacy, safety, tolerability, and pharmacodynamics of SPG302 in adults with a primary diagnosis of schizophrenia.
Clinical Trials are Open in Australia:
NCT06442462
Status: Recruiting
Location
MAPrc, Melbourne VIC, Australia
Contact: Emorfia Gavrilidis at MAPrc
emmy.gavrilidis@monash.edu
For additional information, visit ClinicalTrials.gov
